Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Proof-Of-Concept Study of Metabolically Optimized, Non-Cytotoxic 5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies

NCT04187703 is registered in ClinicalTrials.gov with Benjamin Tomlinson as lead sponsor.

NCT NCT04187703
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04187703 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Proof-Of-Concept Study of Metabolically Optimized, Non-Cytotoxic 5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies
Lead sponsor
Benjamin Tomlinson
Phase
Phase 1
Overall status
Recruiting
Start date
November 16, 2020
Completion date
December 1, 2027
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mds/mpn crossover syndromes, myelodysplastic syndromes